Cargando…
Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
Individuals with metabolic syndrome are at high risk of developing chronic kidney disease (CKD) through unclear pathogenic mechanisms. Obesity and diabetes are known to induce glucolipotoxic effects in metabolically relevant organs. However, the pathogenic role of glucolipotoxicity in the aetiology...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Limited
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424461/ https://www.ncbi.nlm.nih.gov/pubmed/22773754 http://dx.doi.org/10.1242/dmm.009266 |
_version_ | 1782241216899842048 |
---|---|
author | Martínez-García, Cristina Izquierdo, Adriana Velagapudi, Vidya Vivas, Yurena Velasco, Ismael Campbell, Mark Burling, Keith Cava, Fernando Ros, Manuel Orešič, Matej Vidal-Puig, Antonio Medina-Gomez, Gema |
author_facet | Martínez-García, Cristina Izquierdo, Adriana Velagapudi, Vidya Vivas, Yurena Velasco, Ismael Campbell, Mark Burling, Keith Cava, Fernando Ros, Manuel Orešič, Matej Vidal-Puig, Antonio Medina-Gomez, Gema |
author_sort | Martínez-García, Cristina |
collection | PubMed |
description | Individuals with metabolic syndrome are at high risk of developing chronic kidney disease (CKD) through unclear pathogenic mechanisms. Obesity and diabetes are known to induce glucolipotoxic effects in metabolically relevant organs. However, the pathogenic role of glucolipotoxicity in the aetiology of diabetic nephropathy is debated. We generated a murine model, the POKO mouse, obtained by crossing the peroxisome proliferator-activated receptor gamma 2 (PPARγ2) knockout (KO) mouse into a genetically obese ob/ob background. We have previously shown that the POKO mice showed: hyperphagia, insulin resistance, hyperglycaemia and dyslipidaemia as early as 4 weeks of age, and developed a complete loss of normal β-cell function by 16 weeks of age. Metabolic phenotyping of the POKO model has led to investigation of the structural and functional changes in the kidney and changes in blood pressure in these mice. Here we demonstrate that the POKO mouse is a model of renal disease that is accelerated by high levels of glucose and lipid accumulation. Similar to ob/ob mice, at 4 weeks of age these animals exhibited an increased urinary albumin:creatinine ratio and significantly increased blood pressure, but in contrast showed a significant increase in the renal hypertrophy index and an associated increase in p27(Kip1) expression compared with their obese littermates. Moreover, at 4 weeks of age POKO mice showed insulin resistance, an alteration of lipid metabolism and glomeruli damage associated with increased transforming growth factor beta (TGFβ) and parathyroid hormone-related protein (PTHrP) expression. At this age, levels of proinflammatory molecules, such as monocyte chemoattractant protein-1 (MCP-1), and fibrotic factors were also increased at the glomerular level compared with levels in ob/ob mice. At 12 weeks of age, renal damage was fully established. These data suggest an accelerated lesion through glucolipotoxic effects in the renal pathogenesis in POKO mice. |
format | Online Article Text |
id | pubmed-3424461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Company of Biologists Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-34244612012-09-01 Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model Martínez-García, Cristina Izquierdo, Adriana Velagapudi, Vidya Vivas, Yurena Velasco, Ismael Campbell, Mark Burling, Keith Cava, Fernando Ros, Manuel Orešič, Matej Vidal-Puig, Antonio Medina-Gomez, Gema Dis Model Mech Research Article Individuals with metabolic syndrome are at high risk of developing chronic kidney disease (CKD) through unclear pathogenic mechanisms. Obesity and diabetes are known to induce glucolipotoxic effects in metabolically relevant organs. However, the pathogenic role of glucolipotoxicity in the aetiology of diabetic nephropathy is debated. We generated a murine model, the POKO mouse, obtained by crossing the peroxisome proliferator-activated receptor gamma 2 (PPARγ2) knockout (KO) mouse into a genetically obese ob/ob background. We have previously shown that the POKO mice showed: hyperphagia, insulin resistance, hyperglycaemia and dyslipidaemia as early as 4 weeks of age, and developed a complete loss of normal β-cell function by 16 weeks of age. Metabolic phenotyping of the POKO model has led to investigation of the structural and functional changes in the kidney and changes in blood pressure in these mice. Here we demonstrate that the POKO mouse is a model of renal disease that is accelerated by high levels of glucose and lipid accumulation. Similar to ob/ob mice, at 4 weeks of age these animals exhibited an increased urinary albumin:creatinine ratio and significantly increased blood pressure, but in contrast showed a significant increase in the renal hypertrophy index and an associated increase in p27(Kip1) expression compared with their obese littermates. Moreover, at 4 weeks of age POKO mice showed insulin resistance, an alteration of lipid metabolism and glomeruli damage associated with increased transforming growth factor beta (TGFβ) and parathyroid hormone-related protein (PTHrP) expression. At this age, levels of proinflammatory molecules, such as monocyte chemoattractant protein-1 (MCP-1), and fibrotic factors were also increased at the glomerular level compared with levels in ob/ob mice. At 12 weeks of age, renal damage was fully established. These data suggest an accelerated lesion through glucolipotoxic effects in the renal pathogenesis in POKO mice. The Company of Biologists Limited 2012-09 2012-07-05 /pmc/articles/PMC3424461/ /pubmed/22773754 http://dx.doi.org/10.1242/dmm.009266 Text en © 2012. Published by The Company of Biologists Ltd This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms. |
spellingShingle | Research Article Martínez-García, Cristina Izquierdo, Adriana Velagapudi, Vidya Vivas, Yurena Velasco, Ismael Campbell, Mark Burling, Keith Cava, Fernando Ros, Manuel Orešič, Matej Vidal-Puig, Antonio Medina-Gomez, Gema Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model |
title | Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model |
title_full | Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model |
title_fullStr | Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model |
title_full_unstemmed | Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model |
title_short | Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model |
title_sort | accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424461/ https://www.ncbi.nlm.nih.gov/pubmed/22773754 http://dx.doi.org/10.1242/dmm.009266 |
work_keys_str_mv | AT martinezgarciacristina acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT izquierdoadriana acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT velagapudividya acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT vivasyurena acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT velascoismael acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT campbellmark acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT burlingkeith acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT cavafernando acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT rosmanuel acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT oresicmatej acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT vidalpuigantonio acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel AT medinagomezgema acceleratedrenaldiseaseisassociatedwiththedevelopmentofmetabolicsyndromeinaglucolipotoxicmousemodel |